en · de · es
lab-handbook.peptides6823.com › Guide › Tb-500 Identity And Naming Background — Worked Examples

Tb-500 Identity And Naming Background — Worked Examples

By Editorial Desk · published 2026-06-11 · last reviewed 2026-07-24 · Guide

wound model raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2026-07-24 and is reviewed periodically as new material appears.

TB-500 Identity and Naming Background

Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.

TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.

Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.

Identity And Naming Background

Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.

TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.

Tb-500 at a glance

PropertyValueNotes
Name typeCommercial trade nameNot a systematic chemical identifier
Parent peptideThymosin beta-443-residue natural peptide
Common fragment sequenceLKKTETQMaps to part of the actin-binding region
Molecular size classRoughly 0.8-1.0 kDaDepends on exact fragment and terminal modification
Regulatory statusProhibited in sportGrouped with peptide hormones in many frameworks

Research Framing and Evidence Base

Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.

Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.

Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.

Related pages on this site

TB-500 Identity and Molecular Background

TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.

Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.

Further detail

In addition to the name or initials of the fada, these may include an arrow pointing to the meeting place, or a simple symbol such as a dollar sign, heart, or star. They are primarily intended as signage, not art, though some fadas have complex, technically skilled murals, sometimes commissioned from professional painters. Before cementing and painting a wall, fadas usually seek the approval of property owners, which is usually granted. For some fadas, murals are more important to their visibility than names. Fadas' inscriptions are drawn in various color schemes, often with bold colors that are highly visible against the wall (such as white and cyan). Some fadas paint their benches or teapots with the same colors, or wear matching uniforms. Some images are widespread among fadas, such as teapots, boomboxes, and men wearing Rasta caps. Among complex murals, many depict animals that symbolize toughness; other subjects may be inspired by popular culture, urban notions of coolness, or African American concepts of masculinity. According to Masquelier, writing on walls is a form of placemaking that establishes fadas as part of their cities. It increases their visibility within their neighborhoods, like tagging by graffiti artists, and some are artistically influenced by graffiti. However, they are more legitimate and longer-lasting than graffiti and are not intended as provocative. They also differ from formal signage, being placed on relatively inconspicuous walls.

In addition, although titanium is generally well tolerated by the body, there have been cases where the build-up of titanium particles released by the implant may cause systemic inflammatory response. Because there is no dental enamel on an implant, it does not fail due to cavities like natural teeth. While large-scale, long-term studies are scarce, several systematic reviews estimate the long-term (five to ten years) survival of dental implants at 93–98 percent depending on their clinical use. During initial development of implant retained teeth, all crowns were attached to the teeth with screws, but more recent advancements have allowed placement of crowns on the abutments with dental cement (akin to placing a crown on a tooth). This has created the potential for cement, that escapes from under the crown during cementation to get caught in the gingiva and create a peri-implantitis (see picture below). While the complication can occur, there does not appear to be any additional peri-implantitis in cement-retained crowns compared to screw-retained crowns overall. In compound implants (two stage implants), between the actual implant and the superstructure (abutment) are gaps and cavities into which bacteria can penetrate from the oral cavity. Later these bacteria will return into the adjacent tissue and can cause periimplantitis.

For example, the latter could be reduced with hydrogen to 249CfBr2, but the former could not – this result was reproduced on individual 249BkBr3 and 249CfBr3 samples, as well on the samples containing both bromides. The intergrowth of californium in berkelium occurs at a rate of 0.22% per day and is an obstacle to studying berkelium properties. Beside a chemical contamination, 249Cf, being an alpha emitter, brings undesirable self-damage of the crystal lattice and the resulting self-heating. The chemical effect however can be avoided by performing measurements as a function of time and extrapolating the obtained results.

=== Clinically isolated syndrome === The earliest clinical presentation of relapsing-remitting multiple sclerosis is the clinically isolated syndrome (CIS), that is, a single attack of a single symptom. During a CIS, there is a subacute attack suggestive of demyelination which should be included in the spectrum of MS phenotypes. Treatment with interferons after an initial attack decreases the risk of developing clinical definite MS.

The use of bird skins to document species has been a standard part of systematic ornithology. Bird skins are prepared by retaining the key bones of the wings, legs, and skull along with the skin and feathers. In the past, they were treated with arsenic to prevent fungal and insect (mostly dermestid) attack. Arsenic, being toxic, was replaced by less-toxic borax. Amateur and professional collectors became familiar with these skinning techniques and started sending in their skins to museums, some of them from distant locations. This led to the formation of huge collections of bird skins in museums in Europe and North America. Many private collections were also formed. These became references for comparison of species, and the ornithologists at these museums were able to compare species from different locations, often places that they themselves never visited. Morphometrics of these skins, particularly the lengths of the tarsus, bill, tail, and wing became important in the descriptions of bird species. These skin collections have been used in more recent times for studies on molecular phylogenetics by the extraction of ancient DNA. The importance of type specimens in the description of species make skin collections a vital resource for systematic ornithology. However, with the rise of molecular techniques, establishing the taxonomic status of new discoveries, such as the Bulo Burti boubou (Laniarius liberatus, no longer a valid species) and the Bugun liocichla (Liocichla bugunorum), using blood, DNA and feather samples as the holotype material, has now become possible.

Sources: en.wikipedia.org

Supporting material

=== Tumor-associated neutrophils (TANs) === Tumor-associated neutrophils (TANs) can exhibit an elevated extracellular acidification rate when there is an increase in glycolysis levels. When there is a metabolic shift in TANs this can lead to tumor progression in certain areas of the body, such as the lungs. TANs support the growth and progression of tumors unlike normal neutrophils which would inhibit tumor progression through the phagocytosis of tumor cells. Utilizing a mouse model, they identified that both Glut1 and glucose metabolism increased in TANs found within a mouse who possessed lung adenocarcinoma. A study showed that lung tumor cells can remotely initiate osteoblasts and these osteoblasts can worsen tumors in two ways. First, they can induce SiglecFhigh-expressing neutrophil formation that in turn promotes lung tumor growth and progression. Second, the osteoblasts can promote bone growth thus forming a favorable environment for tumor cells to grow to form bone metastasis.

Werner discovered the spatial arrangements of the ligands that were involved in the formation of the complex hexacoordinate cobalt. His theory allows one to understand the difference between a coordinated ligand and a charge balancing ion in a compound, for example the chloride ion in the cobaltammine chlorides and to explain many of the previously inexplicable isomers. In 1911, Werner first resolved the cobalt/ammonia coordination complex hexol into optical isomers, overthrowing the theory that only carbon compounds could possess chirality.

Diabetic nephropathy See: Nephropathy Diabetic neuropathy See: Neuropathy Diabetic osteopathy Bone disease secondary to chronic diabetes, such as loss of foot bone tissue as viewed by x-ray; often temporary. Also called "disappearing bone disease", although that name can refer to other forms of bone resorption too. Diabetic retinopathy damage to the retina caused by growth of very small blood vessels. The proliferative variety is dangerous and often leads to blindness. It has been the leading non0traumatic cause of blindness in adults in the developed world for much of the 20th century. Diabetogenic Causing diabetes; some drugs cause blood glucose (sugar) to rise temporarily. Other cause it to rise permanently; if so they have caused diabetes. A chemical used as rat poison is an example. Diabetologist A doctor who sees and treats people with diabetes mellitus. Diabulimia (Portmanteau of diabetes and bulimia) An eating disorder where Type 1 diabetics intentionally take less insulin than needed in order to lose weight. Without insulin, glucose becomes unusable and accumulates in the bloodstream (eventually being lost in urine), and the body is forced to use fat for energy. A dangerous practice, not only due to complications of diabetes, but the increased risk of diabetic ketoacidosis. Diagnosis A decision as to the cause of some symptoms or problem. A goal of most physicians is to eliminate as many possible causes as possible (the 'diagnostic differential tree') and so work toward making an affirmative diagnosis. Reaching this point suggests a course of treatment.

== Functions == This vitamer, along with adenosylcobalamin, is one of two active coenzymes used by vitamin B12-dependent enzymes and is the specific vitamin B12 form used by 5-methyltetrahydrofolate-homocysteine methyltransferase (MTR), also known as methionine synthase. Methylcobalamin participates in the Wood–Ljungdahl pathway, which is a pathway by which some organisms utilize carbon dioxide as their source of organic compounds. In this pathway, methylcobalamin provides the methyl group that couples to carbon monoxide (derived from CO2) to afford acetyl-CoA. Acetyl-CoA is a derivative of acetic acid that is converted to more complex molecules as required by the organism. Methylcobalamin is produced by some bacteria. It plays an important role in the environment, where it is responsible for the biomethylation of certain heavy metals. For example, the highly toxic methylmercury is produced by the action of methylcobalamin. In this role, methylcobalamin is the source of "CH3+".

Sources: en.wikipedia.org

Frequently asked questions

Is TB-500 the same as thymosin beta-4?

No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.

What does research on the fragment actually measure?

Published work usually examines actin binding, cell migration and tissue repair endpoints in cell and animal models. Findings are generally described as preliminary, and controlled human data remain limited.

Why does the name cause confusion?

Because TB-500 is a trade name rather than a chemical identifier, different vendors and papers may attach it to different fragment lengths. Checking the stated sequence is the practical way to resolve the ambiguity.

Is TB-500 identical to thymosin beta-4?

No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.

Network